Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE

(GSK)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

GlaxoSmithKline to look for early-stage assets - CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/08/2019 | 01:12pm EDT
FILE PHOTO: GlaxoSmithKline CEO, Emma Walmsley, arrives for a meeting in Downing Street in central London

(Reuters) - GlaxoSmithKline Plc will actively look to buy early-stage assets and partner with companies, the drugmaker's chief executive officer said on Tuesday.

Britain's biggest drugmaker is also likely to evaluate licensing deals and would continue to invest in early-stage HIV treatments, CEO Emma Walmsley said at the JP Morgan healthcare conference in San Francisco.

Walmsley said the company had extensive plans for its experimental drug to treat multiple myeloma, which targets a protein called BCMA, adding that it could be launched by 2020.

On the company's portfolio of cancer medicines, she said GlaxoSmithKline had almost doubled the size of its immuno-oncology pipeline over the past few months.

The company's plan to acquire U.S.-based Tesaro for $5.1 billion (£4 billion) in December is among several large healthcare deals in recent months to pump money into cancer drug development.

That was followed by Bristol-Myers Squibb Co's $74 billion deal to buy Celgene Corp and Eli Lilly & Co's $8 billion acquisition of Loxo Oncology earlier this month.

In what was widely considered a bold move on Walmsley's part, last month GlaxoSmithKline also said it would split into two businesses after forming a new joint venture with Pfizer consumer health division.

(Reporting by Tamara Mathias in Bengaluru; Editing by Arun Koyyur)

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -1.39% 47.49 Delayed Quote.-7.35%
CELGENE CORPORATION -0.26% 87.92 Delayed Quote.37.54%
ELI LILLY AND COMPANY 1.22% 129.87 Delayed Quote.10.87%
GLAXOSMITHKLINE -0.33% 1549.8 Delayed Quote.4.28%
LOXO ONCOLOGY INC 0.00%End-of-day quote.0.00%
PFIZER 0.10% 41.89 Delayed Quote.-4.12%
TESARO INC 0.03% 74.96 End-of-day quote.0.96%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
03/22LONDON STOCK EXCHANGE : FTSE sinks as Brexit relief spurs sterling, weak activit..
RE
03/21GLAXOSMITHKLINE : Reports Positive Data From Blood Cancer Study
DJ
03/21GLAXOSMITHKLINE : GSK announces further positive data from DREAMM-1 study of ant..
PU
03/21GLAXOSMITHKLINE : GSK announces further positive data from DREAMM-1
PU
03/20ADRs End Slightly Lower; BBVA, British American Tobacco and GlaxoSmithKline T..
DJ
03/19GLAXO : Tesaro Asset Dostarlimab Showing Positive Results
DJ
03/19GLAXOSMITHKLINE : GSK reports positive data from trial of endometrial cancer dru..
RE
03/19GLAXOSMITHKLINE : Data from GARNET study evaluating dostarlimab
PU
03/19GLAXOSMITHKLINE : Data from GARNET study indicates robust activity of dostarlima..
PU
03/18GLAXOSMITHKLINE : GSK Annual Report 2018 on Form 20-F
PU
More news
Financials (GBP)
Sales 2019 31 842 M
EBIT 2019 8 520 M
Net income 2019 4 118 M
Debt 2019 24 303 M
Yield 2019 5,14%
P/E ratio 2019 17,37
P/E ratio 2020 16,96
EV / Sales 2019 3,19x
EV / Sales 2020 2,94x
Capitalization 77 227 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 16,4  GBP
Spread / Average Target 5,3%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Paul Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE4.28%102 048
JOHNSON & JOHNSON6.09%364 560
NOVARTIS10.71%239 248
ROCHE HOLDING LTD.10.68%233 745
PFIZER-4.12%232 343
MERCK AND COMPANY7.70%212 409